Our Pipeline

Our pipeline includes innovative product candidates that address the cognitive, functional and behavioral needs of dementia patients. These are investigational new drug candidates and are not approved for any indication in any markets.

Compound Indication Phase Phase I Phase II Phase III Clinical Trials
I II III
Intepirdine
(RVT-101)

5HT6 Receptor Antagonist

Mild-to-Moderate Alzheimer's Disease

Currently in Phase III - View Link

View Link
Dementia with Lewy Bodies (DLB)

Phase II Complete - View Link

View Link
Gait and Balance Impairments in Dementia

Currently in Phase II

Nelotanserin
(RVT-102)

5HT2A Receptor Inverse Agonist

Visual hallucinations in Lewy Body Dementia

Currently in Phase II - View Link

View Link
REM Sleep Behavior Disorder (RBD) in DLB

Phase II Complete - View Link

View Link
RVT-103
& RVT-104

Glycopyrrolate + Cholinesterase Inhibitor Combination

Alzheimer’s Disease

Currently in Phase I

Lewy Body Dementia

Currently in Phase I

Axovant owns worldwide rights to all of our product candidates in development today.